Paris – 28.05.2026: In a significant development for obesity treatment in France, Health Minister Stéphanie Rist announced today that the drugs Wegovy and Mounjaro will now be reimbursed. This decision marks an important step in combating obesity, which affects more than eight million people in France.
Wegovy, a drug from the Danish pharmaceutical company Novo Nordisk, had not been reimbursed in France since its introduction in October 2024, costing patients between 274 and 365 euros per month. With the new reimbursement policy, the price for the first three doses is set at 146.91 euros per month, representing a substantial saving for patients.
The decision to reimburse Wegovy and Mounjaro was made after intensive negotiations between the French Ministry of Health and the manufacturers. These discussions focused on setting a fair price and determining the reimbursement rate through statutory health insurance. Although the exact details of the agreement have not yet been published, the reimbursement is expected to become effective in the second half of 2026.
The reimbursement of these drugs is anticipated to have a significant impact on obesity treatment in France. Experts estimate that the annual costs for reimbursement will be around 100 million euros. This investment is deemed necessary to manage rising healthcare costs related to obesity and to improve the quality of life for affected patients.
Novo Nordisk welcomed the French government’s decision, emphasizing that reimbursing Wegovy represents a significant advance in the fight against obesity. The company also announced that it would lower the price of Wegovy in France to 146.91 euros per month for the first three doses to further enhance the drug’s accessibility.
The introduction of reimbursement for Wegovy and Mounjaro is viewed by health experts as a step in the right direction to improve obesity treatment in France. However, it is emphasized that a comprehensive strategy is required, which besides drug therapies also includes preventive measures and improvement in the population’s dietary habits.
The French government plans to comprehensively inform the public about the reimbursement details and the prescribing conditions for Wegovy and Mounjaro in the coming weeks. Patients interested in treatment with these drugs should consult their general practitioner or specialist to obtain further information and discuss the most suitable therapy option for them.
The decision to reimburse Wegovy and Mounjaro in France is considered a major step in the fight against obesity and could serve as a model for other European countries facing similar challenges. How this decision will affect the prevalence of obesity and associated healthcare costs in France remains to be seen.